MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial

    C. Tanner, D. Chernick, A. Formella (San Francisco, CA, USA)

    Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…
  • MDS Virtual Congress 2020

    Andrograholide protect microglial activation via inhibiting mitochondrial ROS generation and NLRP3 inflammasome activation in in-vitro and in-vivo model of Parkinson’s disease

    S. Ahmed, V. Naidu (Kamrup, India)

    Objective: Parkinson's disease (PD) is a distressing neurodegenerative disorder effecting nearly 2-3% of the total population greater than 65 years old . Several mechanisms have…
  • MDS Virtual Congress 2020

    The add-on effect of Lactobacillus plantarum PS128 in patients with Parkinson’s disease: A pilot study

    H.C Chang, Y.C Tsai, C.S Lu (Taoyuan City, Taiwan)

    Objective: We aimed to investigate the add-on effect of Lactobacillus plantarum PS128 (PS128) in patients with Parkinson’s disease (PD). Background: PS128 is a specific probiotic…
  • MDS Virtual Congress 2020

    Claims Data Analysis of Parkinson’s Disease Medication Utilization

    M. Frazer, C. Blauer-Peterson, R. Sasane, S. Arcona, Y. Fang, R. Halpern (Eden Prairie, MN, USA)

    Objective: Characterize prominent medication utilization patterns among patients with Parkinson’s disease (PD). Background: Multiple classes of medications, as monotherapy or polytherapy, are prescribed to treat…
  • MDS Virtual Congress 2020

    An Analysis of Parkinson’s Disease Medication Treatment Patterns among Medicaid Patients

    M. Johnsrud, K. Richards, R. Sasane, M. Leoni, S. Arcona (Austin, TX, USA)

    Objective: To describe patient demographic and medication utilization patterns within a state Medicaid program for patients diagnosed with Parkinson’s disease (PD). Background: Little is known…
  • MDS Virtual Congress 2020

    Opicapone management: A 2-year follow up real- life practice study

    M. Mata, C. Borrue, M. Almarcha (Madrid, Spain)

    Objective: The aim of this work is to show our clinical experience with opicapone in real practice in a cohort of 68 parkinsonian patients followed…
  • MDS Virtual Congress 2020

    Effectiveness of onabotulinumtoxinA on reduction of rest tremor in Parkinson’s disease: A pilot study

    D. Roque, D. Drazheva, N. Browner, M. Sklerov, M. Collins (Chapel Hill, NC, USA)

    Objective: To determine the feasibility of a prospective study design aimed specifically at comparing the effect of onabotulinumtoxinA (BOT-A) to placebo injections on persons with…
  • MDS Virtual Congress 2020

    Physiologically-based pharmacokinetic modeling of nilotinib to determine serum, cerebrospinal fluid, and brain exposures

    C. Venuto, T. Simuni, B. Fiske, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, J. Adams, L. Trusso, M. Kostrzebski, T. Ward, G. Rafaloff, K. Merchant (Rochester, NY, USA)

    Objective: To construct a physiologically-based pharmacokinetic (PBPK) model for predicting nilotinib pharmacokinetics (PK) in plasma and cerebrospinal fluid (CSF); and, to compare model-predicted serum and…
  • MDS Virtual Congress 2020

    Sleep-related Symptoms in Multiple System Atrophy: Determinants and Impact on disease severity

    J.Y Lin, L.Y Zhang, B. Cao, QQ. Wei, H.F Shang (Chengdu, China)

    Objective: To investigate the prevalence and determinants of sleep-related symptoms in multiple system atrophy (MSA) and the impact of sleep disturbances on disease severity. Background:…
  • MDS Virtual Congress 2020

    Morphology and Signal Changes of the Lentiform Nucleus Based on Susceptibility Weighted Imaging in Parkinsonism predominant Multiple System Atrophy

    C.P Zhao, Q.G Ren (Qindao, China)

    Objective: This present case-control study was aimed to investigate both morphological and signal intensity changes in susceptibility weighted imaging(SWI) of the Lentiform Nucleus (LN) for…
  • « Previous Page
  • 1
  • …
  • 73
  • 74
  • 75
  • 76
  • 77
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Welcome to the MDS Abstracts Site
  • Effect of marijuana on Essential Tremor: A case report
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley